Abstracts tagged "Health Assessment Questionnaire (HAQ)"

Abstract Number: 1708 • ACR Convergence 2025
Assessing Social Determinants of Health Using PRAPARE in a Rheumatology Patient Navigator Program for Underserved Brooklyn Communities
Meenakshi Kurup¹, Jasmine Pak², Alyssa Carlson², Beylul Negassi², Callie Sacks², Ettiman Kaur², Fanyu Hercules-Tawe², Gabriel Cruz², Julia Fisher², Grace Shadid², Hadar Shimshon², Maria Botero Pinzon², Naureen Kabani², Sharon Glick² and Ellen Ginzler³, ¹SUNY Downstate Health Sciences University, Brooklyn, NY, ²SUNY Downstate Health Sciences University, Brooklyn, ³SUNY Downstate Health Sciences University, New York, NY
Background/Purpose: Social determinants of health (SDoH) contribute significantly to disparities in care but are rarely addressed in subspecialty settings. The PRAPARE (Protocol for Responding to…
Abstract Number: 1375 • ACR Convergence 2025
86-96% of rheumatoid arthritis (RA) patients with RA who have 0 or 1 swollen joint or tender joint but are classified as moderate/high on RA indices have 1-9 comorbidities recognized on a multidimensional health assessment questionnaire (MDHAQ)
Theodore Pincus¹, Juan Schmukler¹ and Tengfei Li², ¹Rush University Medical Center, Chicago, IL, ²Rush, chicago, IL
Background/Purpose: Rheumatoid arthritis (RA) guidelines suggest management according to “treat-to-target,” with escalation of treatment in patients with moderate/high (M/H) DAS28 (disease activity score 28) or…
Abstract Number: 1103 • ACR Convergence 2025
Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Kayla Chubbs¹, Carrie Ye², Shahin Jamal³, Marie Hudson⁴, Janet Pope⁵, Tom Appleton⁶, Sabrina Hoa⁷, Alexandra Saltman⁸, Megan Himmel⁸, Nancy Maltez⁹, Faiza Khokhar¹⁰, Alexandra Ladouceur¹¹, Ines Colmegna¹², May Choi¹³, Manar Elsayed² and Janet Roberts¹, ¹Dalhousie University, Halifax, NS, Canada, ²University of Alberta, Edmonton, AB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montréal, QC, Canada, ⁵University of Western Ontario, London, ON, Canada, ⁶Western University, London, ON, Canada, ⁷University of Montreal, Brossard, QC, Canada, ⁸University of Toronto, Toronto, ON, Canada, ⁹Department of Medicine, Division of Rheumatology, The Ottawa Hospital, University of Ottawa, Ottawa, Canada., Ottawa, ON, Canada, ¹⁰Hamilton Ontario, Hamilton, ON, Canada, ¹¹University of Montreal, Montreal, QC, Canada, ¹²The Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ¹³University of Calgary, Calgary, AB, Canada
Background/Purpose: The use of immune checkpoint inhibitors (ICI) continues to increase with an expanding number of indications across varying cancer types and stages. ICIs can…
Abstract Number: 0444 • ACR Convergence 2025
Low Disease Activity: Good Enough?
Emily Thoman¹, Sebastiano Porcu¹ and Martin Bergman², ¹Lankenau Medical Center, Wynnewood, PA, ²Drexel University College of Medicine, Philadelphia
Background/Purpose: Treat-to-target is the guiding principle and therapeutic strategy for rheumatoid arthritis (RA) treatment. Escalation of treatment is based on the regular assessment of disease…
Abstract Number: 0199 • ACR Convergence 2025
Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study
Abebawork Adem¹, Alfonso Sucerquia², Jose Forero³, Juan Alzate², Larry Moreland⁴, Gary Firestein⁵, Andres Cadena⁶ and Aileen Chang⁷, ¹George Washington University, Washington, DC, DC, ²The George Washington University, Arlington, ³The George Washington University, Arlington, VA, ⁴University of Colorado, Denver, CO, ⁵University of California, San Diego, San Diego, CA, ⁶Clinica de la Costa, Barranquilla, Colombia, ⁷The George Washington University, Washington
Background/Purpose: Chronic chikungunya arthritis (CCA) is a long-term sequela of chikungunya virus infection marked by persistent pain, disability, and reduced quality of life. While nociplastic,…
Abstract Number: 0703 • ACR Convergence 2024
Preliminary Results from the RECONNOITER Trial, a Phase 2 Study of AISA 021 in the Treatment of Secondary Raynaud’s, Primarily Due to Systemic Sclerosis
Andrew Sternlicht¹, Michael Shanahan², Erin Morton², Meredith Todd³, Ivana Hunt², Zoey Reed², amanda weragoda⁴, Lashika Weerakoon² and Elizabeth Briggs², ¹Tufts University Medical Center and Aisa Pharma, Inc., Boston, MA, ²Flinders Medical Centre, Adelaide, Australia, ³Aisa Pharma Pty Ltd., East Lindfield, New South Wales, Australia, ⁴F, Adelaide, Australia
Background/Purpose: While 95% of Systemic Sclerosis (SSc) patients have Raynaud’s phenomenon(RP) and many patients rate it as the most bothersome and severe symptom of their…
Abstract Number: 1360 • ACR Convergence 2024
Impact of Maintaining Low Disease Activity on Patient Outcomes and Healthcare Resource Utilization in Rheumatoid Arthritis Patients Receiving Advanced Treatment
Urbano Sbarigia¹, Jing Zhao², Jackie Kwong², Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Johnson & Johnson Innovative Medicine, Brussels, Belgium, ²Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Despite scientific advances and the availability of new treatments for rheumatoid arthritis (RA), many RA patients still cannot achieve the therapeutic goal of low…
Abstract Number: 1743 • ACR Convergence 2024
What Are the Benefits of Treating Rheumatoid Arthritis Patients to Remission After Achieving Low Disease Activity in Clinical Practice?
Jing Zhao¹, Urbano Sbarigia², Jackie Kwong¹, Chinmayi Naik³, Federico Zazzetti⁴, Nancy Shadick³ and Michael Weinblatt⁵, ¹Janssen Global Services, LLC, a Johnson & Johnson Company, Raritan, NJ, ²Johnson & Johnson Innovative Medicine, Brussels, Belgium, ³Brigham and Women’s Hospital, Boston, MA, ⁴Johnson & Johnson Innovative Medicine, Horsham, PA, PA, ⁵Brigham and Women's Hospital/ Harvard Medical School, Waban, MA
Background/Purpose: Current treatment guidelines for rheumatoid arthritis (RA) recommend low disease activity (LDA) as initial treatment goal with remission as a subsequent target whenever possible.…
Abstract Number: 2015 • ACR Convergence 2024
Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy
Austin Barry¹, Harlan Sayles¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Kaleb Michaud¹, Bridget Kramer¹, Jeff Newcomb¹, Mary Brophy³, Anne Davis-Karim⁴, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁵, Tuhina Neogi⁶, Paul Palevsky⁷, James O'Dell¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Veterans Affairs, Boston, MA, ⁴Veterans Affairs, Albuquerque, NM, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is associated with decreased health-related quality of life (HRQoL). The ACR endorses treat-to-target (TtT) urate-lowering therapy (ULT) for gout with a serum urate…
Abstract Number: 2214 • ACR Convergence 2024
Confirming a Value for Rheumatoid Arthritis Flares Based on Changes in CDAI, SDAI and RAPID3
Irtza Badar¹ and Martin Bergman², ¹Mercy Catholic Medical Center, Philadelphia, PA, ²self, Beach Haven, NJ
Background/Purpose: To determine and revalidate the definitions of disease flares in patients with rheumatoid arthritis (RA) flares based on the changes in Clinical and Simplified…
Abstract Number: 2453 • ACR Convergence 2024
Gastrointestinal Symptom Severity and Intestinal Permeability in Systemic Sclerosis: A Single Center Prospective Study
Elvira Lesmana¹, Ashley Keehn², Anukul Karn³, Andrea Pauly⁴, Margaret Breen-Lyles², Adam L Edwinson², Madhusudan Grover⁵ and Ashima Makol⁵, ¹Mayo Clinic, Rochester, MN, New York, NY, ²Mayo Clinic, Rochester, MN, Rochester, ³Mayo Clinic, Rochester, MN, Farmington Hills, MI, ⁴Mayo Clinic Rochester, Rochester, MN, ⁵Mayo Clinic, Rochester, MN, Rochester, MN
Background/Purpose: Systemic Sclerosis (SSc) is a complex, heterogeneous, multisystem autoimmune disease with high morbidity and mortality. Gastrointestinal symptoms impact more than 90% of SSc patients,…
Abstract Number: 0122 • ACR Convergence 2024
Association of Cognitive Impairment Measured by Montreal Cognitive Assessment and Plasma Levels of Growth Differentiation Factor 15 in Patients with Antiphospholipid Antibody Syndrome
Evelyn Aranda Cano¹, Jessica Roldan Ortega², Yaneli Juárez-Vicuña³, Fausto Sánchez Muñoz⁴, Itzel Palafox Sosa⁵, Luz Angelica Viruel-Mejia⁶, David Vera Bustamante⁷, Luis H. Silveira Torre⁸, Angélica Vargas Guerrero⁹, Mayra Nadia Quintanar-Cuevas¹⁰, Erick Giovanny Bautista Jímenez¹¹ and Laura Aline Martinez-Martinez¹², ¹Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de Mexico, Mexico, ²Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, ³Instituto Nacional del Cardiología Ignacio Chávez, México, Distrito Federal, Mexico, ⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, ⁵Escuela Superior de Medicina-Instituto Politecnico Nacional, Ciudad de México, Mexico, ⁶Rheumatology Departement at National Institute of Cardiology Ignacio Chavez - Universidad Autonoma del Estado de Hidalgo, Tula de Allende, Hidalgo, Mexico, ⁷Benemerita Universidad Autonoma de Puebla, Heroica Puebla de Zaragoza, Puebla, Mexico, ⁸Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., Mexico City, Mexico, ⁹Department of Rheumatology , Instituto Nacional de Cardiología Ignacio Chávez., México, Mexico, ¹⁰Mental health outpatient clinic of the National Institute of Cardiology Ignacio Chavez, México, Mexico, ¹¹Hospital General de Zona No. 27 del Instituto Mexicano del Seguro Social, Mexico, Distrito Federal, Mexico, ¹²Rheumatology Department - National Institute of Cardiology Ignacio Chavez, Mexico City, Distrito Federal, Mexico
Background/Purpose: Growth differentiation factor 15 (GDF-15), is a stress induced inflammatory cytokine, member of the transforming growth factor-β superfamily, tissue injury. It is predominantly expressed…
Abstract Number: 0355 • ACR Convergence 2024
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Vibeke Strand¹, Puja Khanna², Alan Kivitz³, Nana Kragh⁴, Aletta Falk⁵, Rehan Azeem⁶, Hugues Santin-Janin⁷ and Herbert Baraf⁸, ¹Division of Immunology/Rheumatology, Stanford University, Palo Alto, CA, ²University of Michigan, Ann Arbor, MI, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Sobi, Kongens Lyngby, Denmark, ⁵Sobi, Stockholm, Sweden, ⁶Sobi Inc., Waltham, MA, ⁷Sobi, BETTENDORF (68560), France, ⁸Center for Rheumatology and Bone Research, Wheaton, MD
Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…
Abstract Number: 0495 • ACR Convergence 2024
Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Manuel Ugarte-Gil², Risto Perich³, Cesar Pastor⁴, Graciela Alarcon⁵ and RV, Gamboa-Cardenas⁶, ¹Hncase, Arequipa, Peru, ²Universidad Cientifica del Sur, Lima, Lima, Peru, ³Hospital Almenara, Lima, Peru, ⁴UNMSM, LIMA, Peru, ⁵The University of Alabama at Birmingham, Oakland, CA, ⁶Universidad Científica del Sur, Lima, Lima, Peru
Background/Purpose: The triglyceride/glucose index (TGI) is a metabolic marker associated with insulin resistance and cardiovascular risk. In patients with Rheumatoid Arthritis (RA), chronic inflammation and…
Abstract Number: 0496 • ACR Convergence 2024
Dissecting Early RA Patient Trajectories Through Time-independent Disease State Identification Identifies Distinct Patterns Dissected by Inflammation in Blood or Joints
Nils Steinz¹, Tjardo Maarseveen², Andrew Cope³, John Isaacs⁴, Aaron Winkler⁵, Thomas Huizinga⁶, Yann Abraham⁷ and Rachel Knevel¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Wormerveer, Netherlands, ³King's College London, London, United Kingdom, ⁴Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, ⁵Pfizer Inc., Cambridge, MA, ⁶Department of Rheumatology, Leiden University, Leiden, Netherlands, ⁷Janssen Research and Development, Beerse, Belgium
Background/Purpose: Patients with RA display different trajectories in the improvement of disease activity. Discerning the RA trajectories, how they differ between patients and which factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].